M1RN34 trade ideas
MRNA follow the break out strong bullish move. "MRNA's breakout has been confirmed with a strong bullish pattern formed. Ride the trade with an open target and trail the stop loss to secure gains."
MRNA Moderna Options Ahead of EarningsIf you haven`t sold MRNA at all time high:
Then analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week,
I would consider purchasing the 115usd strike price Calls with
an expiration date of 2024-7-19,
for a premium of approximately $8.00.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Moderna Breaks Out 12.68% For The First Time In A YearModerna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due to make its decision on Moderna's shot in less than two weeks. Moderna ( NASDAQ:MRNA ) hopes to launch its vaccine for older adults this fall. If approved, this would be Moderna's second commercial product behind its Covid vaccine.
Moderna's Covid vaccine sales plummeted nearly 91% to $167 million during the first quarter, but handily beat analysts' forecast for $93 million. The European Union plans to buy up to 36 million doses of its Covid vaccine each year for at least four years. The company expects "higher vaccination uptake" in the U.S. if its updated Covid vaccine is available in time with the seasonal flu shot.
From a financial standpoint, Moderna ( NASDAQ:MRNA ) is retaining its outlook for the year. The company expects to notch $4 billion in sales of its respiratory vaccines. That will be weighted to the back half of the year with less than $300 million in sales projected for the first half of 2024. Moderna ( NASDAQ:MRNA ) stock analysts project $4.19 billion in full-year revenue, including $4.06 billion in sales from the company's products.
The RSV vaccine could be a big moneymaker for Moderna ( NASDAQ:MRNA ). Pfizer and GSK launched their RSV shots for older adults last year, with Abrysvo and Arexvy generating $145 million and $228 million in sales respectively. Moderna stock analysts already expect some sales of Moderna's product — $10 million in the June quarter, according to FactSet.
Moderna is ( NASDAQ:MRNA ) also planning to work with U.S. regulators on the timing of its next Covid vaccine. Officials will choose the next variant to target in booster shots on May 16, then it will be off to the races, so to speak, to run testing for Moderna's updated shot. Moderna's goal is to launch the Covid booster shot in timing with the fall flu vaccine campaign.
CSP IdeaJust sold CSP as shown. Apparently is forming an inverse HS to break out the triangle. It's early to tell but we have good support underneath.
Moderna's Vaccine Spark Hope in Head and Neck Cancer TreatmentIn a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology research.
The vaccine, mRNA-4157, aims to train the immune system to identify and combat specific mutations present in cancer cells, representing a pioneering approach in personalized cancer therapy. Following its success in treating melanoma, the vaccine has now demonstrated positive responses in patients with head and neck squamous cell carcinoma, a challenging form of cancer.
Data presented at the American Association for Cancer Research Annual Meeting showcased the vaccine's efficacy when administered in combination with Merck's Keytruda. The study, involving 22 patients, revealed promising clinical responses, including instances of complete remission. Notably, the combination therapy not only triggered robust immune responses but also exhibited favorable safety profiles, marking a significant milestone in cancer immunotherapy.
Jefferies analyst Michael Yee lauded the results, highlighting the potential of Moderna's therapy platform to transcend melanoma and extend its benefits to other cancer types. The data underscore the transformative potential of mRNA-based vaccines in revolutionizing cancer treatment paradigms and offering new hope to patients grappling with advanced malignancies.
The positive outcome has bolstered investor confidence in Moderna ( NASDAQ:MRNA ), propelling its shares to a three-month high. This uptrend reflects renewed enthusiasm for the biotech firm's diverse pipeline, which includes groundbreaking vaccines targeting respiratory syncytial virus and other infectious diseases, alongside innovative cancer therapies.
Looking ahead, Moderna's collaboration with Merck signals a concerted effort to advance the development of cancer immunotherapies. The initiation of a Phase 3 trial targeting lung cancer underscores the commitment to translating promising preclinical data into clinically meaningful outcomes, to deliver transformative therapies to patients in need.
As Moderna ( NASDAQ:MRNA ) continues to pioneer the frontier of mRNA-based therapeutics, the recent success of its cancer vaccine heralds a new era in precision medicine. With further advancements and clinical validations, this innovative approach holds the potential to reshape the landscape of cancer treatment and offer renewed hope for patients battling this devastating disease.
This is why vax stocks are going to explode from here ! I have looked at the charts of Moderna and explained why I'm so bullish this stock as well as the general sector. We should expect a catalyst show up in the news in the very near future which should cause a big spike in this sector and that cannot be good for the overall market.
Given a breakout of this area we should see a great climbHere's a small interesting history:
In the late 19th century, stock trading took place through an archaic system of handwritten ledger entries and paper shares that had to be physically transported between offices. This cumbersome process led to frequent errors and delays. In 1887, a group of Wall Street clerks devised a more efficient method by setting up networks of pneumatic tubes to rapidly shuttle documents between brokerage houses and the exchange floor. This "mail tube" system, patented in 1892, could propel cylindrical cartridges containing stock certificates and instructions through a maze of underground pipes at speeds of up to 35 mph - a revolutionary breakthrough for finance at the time. The pneumatic tube network grew to span 27 miles of subterranean tubing and remained an integral part of Wall Street trading until the 1960s when it was replaced by digital tickertapes and information networks.
Looking bearish soon on MRNA.🔉Sound on!🔉
Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
MRNA a long-short term lookIf one examines MRNA on the shorter term, the prospective is not so bright.
s3.tradingview.com
However, when one also examines the longer term, clear accumulation can be seen.
s3.tradingview.com
$MRNA Bearish to Bullish Reversal NASDAQ:MRNA Bearish to Bullish Reversal
A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a bullish phase. It could signify a potential turning point in market sentiment, with investors becoming more optimistic about the stock's future prospects. Traders often look for confirmation signals to validate this reversal, such as increased trading volume or positive fundamental developments in the company.
Moderna Surge as it Dives into Promising Cancer Vaccine TrialsModerna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be attributed to several key factors that are igniting investor enthusiasm and confidence in the company's future prospects.
One of the primary catalysts driving Moderna's stock rally is the initiation of a mid-stage clinical trial for its experimental cancer vaccine targeting cutaneous squamous cell carcinoma, a prevalent form of skin cancer. This groundbreaking trial, conducted in collaboration with Merck, underscores Moderna's commitment to pioneering innovative solutions in oncology.
In addition to advancements in oncology, Moderna ( NASDAQ:MRNA ) continues to make significant strides in addressing infectious diseases, oncology, and rare diseases. Despite the challenges posed by the endemic market, Moderna ( NASDAQ:MRNA ) reported notable pipeline advancements in its fourth-quarter results. The company anticipates initial regulatory approvals for its RSV vaccine (mRNA-1345) starting in the first half of 2024, further bolstering its position in the market.
Moreover, Moderna ( NASDAQ:MRNA ) remains optimistic about its COVID-19 franchise, projecting profitability in anticipated sales scenarios for 2024 and beyond. With approximately $4 billion in product sales expected in 2024, primarily driven by COVID-19 vaccine sales and the launch of its RSV vaccine, Moderna is poised for robust growth in the coming years.
Technical Analysis
Shares of Moderna ( NASDAQ:MRNA ) is exhibiting a bullish Flag pattern indicating the NASDAQ:MRNA has reacted to the Promising Cancer Vaccine Trials news. With a moderate Relative Strength Index (RSI) of 68.74 NASDAQ:MRNA shares is gaining momentum.
Looking ahead, Moderna's pipeline update revealed a promising outlook, with 45 therapeutic and vaccine programs, nine of which are in late-stage development. Notably, the Phase 3 trial of its combination vaccine against seasonal flu and COVID-19 has been fully enrolled, with data expected in 2024. These developments underscore Moderna's commitment to innovation and its potential to deliver groundbreaking therapies to address critical unmet medical needs.
In conclusion, Moderna's recent stock rally reflects growing optimism and confidence in the company's innovative pipeline, particularly in the areas of oncology and infectious diseases. With promising clinical trials underway and a robust portfolio of vaccine candidates, Moderna is well-positioned to capitalize on emerging market opportunities and drive long-term value for investors. As the company continues to make strides in pioneering mRNA technology, investors can expect Moderna to remain at the forefront of medical innovation, potentially revolutionizing the treatment landscape for various diseases, including cancer.
Broader wave-3 forming upNASDAQ:MRNA seems to have found its feet in wave 2. We should be now gearing up for wave 3, price action to get more promising upwards as we cross the diagonal resistance (red line).
More on it:
- iH&S shoulder also forming on weekly
- While the monthly close of Jan wasn't promising, buyers stepped into Feb with a decent closure
Disclaimer: This is not financial advice. Please make your own decisions while investing.
Pharmaceutical Giants Stocks: Macro Fib SchematicsThe biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants.
Support and Resistance is clear with these schematics. All clusters are laid over appropriately.
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is
lurking in the shadows and trying to make a comback. It had an excellent earnings report and
forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored
VWAP and is at the level of the first upper VWAP while in side the high volume area of the
volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing
position here and again the next time I see a dip on the 15-30-minute chart. I look forward
to take a piece out of the position after the next earnings report in about 75 days. I have an
alert for relative volume when the running mean is exceeded on the 30 minute chart which
notify me to take a look at the chart. This is illustrated on this longer time frame chart about
the days around earnings but occurs from time to time from other events. As an aside, if NVAX
gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be
the leading candidate to do a takeover, friendly or otherwise.
MODERNA BULLISH RUN AHEAD The mRNA stock has exhibited a bullish flag breakout, following the identification of a falling wedge pattern. We anticipate a potential retracement towards the prominent key level near $130, which was established at the top.
Moderna's Surprising Profit Signals Post-Pandemic PivotModerna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause.
Unveiling the Numbers:
Moderna's ( NASDAQ:MRNA ) fourth-quarter profit stood at a commendable $217 million, or 55 cents a share, defying analyst expectations of a substantial loss. This unexpected triumph was fueled by a combination of factors, including unforeseen deferred revenue and a strategic overhaul in manufacturing operations. The company's ability to navigate challenges and adapt swiftly underscores its agility and forward-thinking approach.
Navigating the COVID-19 Landscape:
While Moderna's COVID-19 vaccine continues to be its flagship product, generating substantial revenue, the company is strategically diversifying its portfolio. Despite a decline in COVID vaccine sales from 2022 to 2023, Moderna ( NASDAQ:MRNA ) remains steadfast in its commitment to innovation. The imminent approval decision for its respiratory syncytial virus (RSV) shot marks a significant milestone in this diversification strategy, offering a glimpse into the company's post-pandemic roadmap.
Looking Beyond COVID:
Moderna's ( NASDAQ:MRNA ) ambitious roadmap extends far beyond the realm of COVID-19. With plans to launch its RSV shot in key markets and a robust pipeline of experimental shots targeting influenza, cancer, and cytomegalovirus, the company is poised for a transformative journey. Despite concerns over efficacy declines compared to rival offerings, Moderna's ( NASDAQ:MRNA ) unwavering focus on research and development signals a bold leap into uncharted territories.
International Endeavors:
Moderna's ( NASDAQ:MRNA ) participation in the EU Health Emergency and Response Authority’s tendering procedure underscores its commitment to global health initiatives. By prioritizing key international markets and aligning with strategic partners, the company aims to broaden its reach and impact. The forthcoming decision on the EU tender is poised to shape the company's trajectory in the global arena, setting the stage for future collaborations and expansions.
Charting the Course Ahead:
As Moderna ( NASDAQ:MRNA ) reaffirms its 2024 forecast amidst shifting market dynamics, the company remains steadfast in its pursuit of excellence. With a projected $4 billion in sales and a focus on operational execution, Moderna ( NASDAQ:MRNA ) is poised to navigate challenges and seize opportunities in the years ahead.
Conclusion:
Moderna's ( NASDAQ:MRNA ) unexpected profit surge and strategic roadmap offer a compelling narrative of resilience and innovation in a rapidly evolving landscape. With eyes set on new horizons and a steadfast resolve, Moderna ( NASDAQ:MRNA ) emerges as a beacon of hope in the post-pandemic world.
Bounce to $120-129 in wave-5?MRNA seems to finding its feet part of wave-4. If market continues to hold current levels, and goes above..it can hit $120-129 part of wave-5.
Disclaimer: This is not financial advice. Please make your own decisions while making an investment.
Was it punished enough?Looks like the market is giving a break to this stock. I think is going to try the 95 resistance level. Looks oversold and bouncing up from a long term trendline. Also call options is an interesting choice but give it time like a month.
Moderna Inc trading idea (10/01/2024)Analysts at the Oppenheimer brokerage company, as reported by Reuters , have upgraded the stock rating of Moderna Inc. to "outperforming the market," and the vaccine maker's CEO reiterated the company's goal of achieving sales growth by 2025.
The issuer's shares fell nearly 45% in 2023, marking its worst annual performance due to weak COVID-19 vaccine sales. According to Oppenheimer, Moderna could have five products on the market by 2026.
So, today, we will examine the Moderna Inc. (NASDAQ: MRNA) stock chart.
On the D1 timeframe, there is a "break" in the downward trend, which has persisted since the end of 2022. Resistance has formed at 115.81, with support at 97.91. Currently, an upward trend is developing on the chart.
On the H1 timeframe, if there is a rebound from the 100.98 level, the short-term target for a price increase can be set at 115.81, while in the medium term, it could hover around 139.77.
—
Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews.
The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments.
Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 66.02% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
$MRNA pushing above 200EMA strongly NASDAQ:MRNA is taking a breather now but looking to break the 115 mark to move higher.
Riding the Wave: The Bullish Case for MRNA’s Inverted Scallop In the dynamic world of stock trading, there are some patterns which emerge that tell a story of market sentiment, investor behavior, and potential future movements. One such narrative is unfolding with Moderna Inc. (MRNA), where an intriguing pattern has caught my eye as we've seen a price rebound since November 2nd, 2023, the inverted scallop. The inverted scallop is not a well known pattern, but renowned candle expert Thomas Bulkowski identifies it as an important one. You can see what Bulkowski says about this pattern here: thepatternsite.com
The Inverted Scallop: A Sign of Reversal
The inverted scallop pattern, resembling a reverse ‘J’, is a bullish reversal pattern that signals a potential shift in momentum. For MRNA, this pattern began to form after a long-term downtrend, with the stock plummeting from a high of $456.76 to a low of $71.23. However, the tide seems to be turning, with the price curving upwards in a recovery that mirrors the shape of an inverted scallop shell. Bulkowski shows an example of this pattern with the price action of Boeing in 2005. It bares a striking resemblance to what we are seeing with MRNA today.
Confirming the Pattern with Technical Indicators
While the scallop pattern itself is compelling, confirmation from other technical indicators is crucial for a robust bullish thesis:
- Divergence: The presence of bullish divergence, where the price hits a lower low while an oscillator forms a higher low, suggests that the downtrend is losing steam.
- Chaikin Money Flow (CMF): A positive CMF value during the formation of the scallop pattern indicates buying pressure and accumulation, reinforcing the bullish outlook.
- Resistance Breakout: A key factor for the pattern’s confirmation is the breakout above significant resistance levels. For MRNA, breaking past the resistance zone between $86.02 and $87.11, as well as subsequent levels at $89.90 and $97.28, would validate the reversal.
Market Psychology: Reading Between the Lines
The long-term downtrend followed by the inverted scallop pattern reflects a shift in market psychology. Initially driven by fear, the potential reversal indicates a change towards optimism, as investors begin to recognize value and anticipate a positive future for MRNA. We see this in the fundamental analysis of MRNA with the news of their recent success in phase 2 studies on cancer vaccines.
Conclusion: A New Chapter for MRNA?
As MRNA’s price action paints a picture of recovery, the inverted scallop pattern offers hope for the continuation of a bullish reversal. Supported by technical indicators and a change in market sentiment, the narrative suggests that MRNA could be on the cusp of a new chapter.
